Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas.

Valkov A, Kilvaer TK, Sorbye SW, Donnem T, Smeland E, Bremnes RM, Busund LT.

J Transl Med. 2011 Nov 22;9:200. doi: 10.1186/1479-5876-9-200.

PMID:
22107784
2.

Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas.

Valkov A, Sorbye S, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, Busund LT.

Int J Oncol. 2011 Apr;38(4):1031-40. doi: 10.3892/ijo.2011.920. Epub 2011 Jan 24.

PMID:
21271213
3.

Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.

Al-Saad S, Donnem T, Al-Shibli K, Persson M, Bremnes RM, Busund LT.

Anticancer Res. 2009 Oct;29(10):4175-83.

PMID:
19846969
4.

The prognostic impact of TGF-β1, fascin, NF-κB and PKC-ζ expression in soft tissue sarcomas.

Valkov A, Sorbye SW, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, Busund LT.

PLoS One. 2011 Mar 3;6(3):e17507. doi: 10.1371/journal.pone.0017507.

PMID:
21390241
5.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.

Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2.

PMID:
20813970
6.

Activation of PI3K is associated with reduced survival in renal cell carcinoma.

Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, Stenzl A, Kuczyk MA.

Urol Int. 2008;80(4):372-7. doi: 10.1159/000132694. Epub 2008 Jun 27.

PMID:
18587247
7.

Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.

Capodanno A, Camerini A, Orlandini C, Baldini E, Resta ML, Bevilacqua G, Collecchi P.

Hum Pathol. 2009 Oct;40(10):1408-17. doi: 10.1016/j.humpath.2009.02.005. Epub 2009 May 9.

PMID:
19428048
8.

[Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].

Yang X, Dong Y, Zhang XM, Liang Y, Zhang Y, Meng YT, Wang Y, Wang W, Nong L, Li T, Liao QP.

Zhonghua Bing Li Xue Za Zhi. 2011 Dec;40(12):799-804. Chinese.

PMID:
22336203
9.

Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma.

Freudlsperger C, Horn D, Weißfuß S, Weichert W, Weber KJ, Saure D, Sharma S, Dyckhoff G, Grabe N, Plinkert P, Hoffmann J, Freier K, Hess J.

Int J Cancer. 2015 Jun 15;136(12):2775-85. doi: 10.1002/ijc.29328. Epub 2014 Nov 26.

PMID:
25388642
10.

ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.

Wang J, Zhang C, Chen K, Tang H, Tang J, Song C, Xie X.

Breast Cancer Res Treat. 2015 Jul;152(2):255-69. doi: 10.1007/s10549-015-3467-3. Epub 2015 Jun 13.

PMID:
26070269
11.

Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.

Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, Botti G, Malanga D, Viglietto G.

PLoS One. 2012;7(2):e30427. doi: 10.1371/journal.pone.0030427. Epub 2012 Feb 17.

PMID:
22363436
12.

Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.

Okutur K, Bassulu N, Dalar L, Aydin K, Bozkurt M, Pilanci KN, Dogusoy GB, Tecimer C, Mandel NM, Demir G.

Asian Pac J Cancer Prev. 2015;16(7):2645-51.

PMID:
25854340
13.

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.

Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.

Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.

PMID:
23728071
14.
15.

PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD, Weiss WA, Berger MS, Gupta N, Haas-Kogan DA.

Neuro Oncol. 2012 Sep;14(9):1146-52. doi: 10.1093/neuonc/nos140. Epub 2012 Jun 29.

PMID:
22753230
16.

PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.

Rogers HA, Mayne C, Chapman RJ, Kilday JP, Coyle B, Grundy RG.

Clin Cancer Res. 2013 Dec 1;19(23):6450-60. doi: 10.1158/1078-0432.CCR-13-0222. Epub 2013 Sep 27.

PMID:
24077346
17.

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.

Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19.

PMID:
21594665
18.

PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).

Li J, Dang Y, Gao J, Li Y, Zou J, Shen L.

Med Oncol. 2015 Apr;32(4):111. doi: 10.1007/s12032-015-0554-6. Epub 2015 Mar 11.

PMID:
25757539
19.

Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients.

Kilvaer TK, Valkov A, Sorbye SW, Smeland E, Bremnes RM, Busund LT, Donnem T.

J Transl Med. 2011 Jul 6;9:104. doi: 10.1186/1479-5876-9-104.

PMID:
21733164
20.

Expression of PI3K, PTEN and Akt in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology.

Zhang Y, Yao X, Jiang C, Yue J, Guan J, Cheng H, Hajirashid M, Wang Y, Fan L.

Cancer Biomark. 2013;13(4):299-305. doi: 10.3233/CBM-130352.

PMID:
24240591

Supplemental Content

Support Center